Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00324077
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Withdrawn
Phase Phase 1
Start date August 2006

See also
  Status Clinical Trial Phase
Completed NCT02348957 - Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
Terminated NCT00114959 - Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Phase 2
Completed NCT00123474 - Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Phase 3
Completed NCT00510926 - Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase Phase 2